Our Products
McNeil Pediatrics currently markets the following prescription pharmaceutical products in the United States. This information is intended for use by our customers, patients and healthcare professionals in the United States only.
|
CONCERTA®, was the first methylphenidate product that lasts through 12 hours with one morning dose. It is a once-a-day treatment for Attention Deficit Hyperactivity Disorder, or ADHD, and contains the drug methylphenidate, a central nervous system stimulant that has been used for more than 50 years. CONCERTA® is indicated for the treatment of ADHD in patients age 6 - 17 as part of a comprehensive treatment program. |
For more information about ADHD and CONCERTA®, visit www.concerta.net for consumer information and www.concerta360.com for healthcare professional information
See Important Safety Information for CONCERTA® below.
CONCERTA® Full U.S. Prescribing Information and Medication Guide
For information on PANCREASE® MT (pancrelipase), please see Full U.S. Prescribing Information
For information on FLEXERIL® (cyclobenzaprine HCI) Tablets, please see Full U.S. Prescribing Information
IMPORTANT SAFETY INFORMATION
Talk to your doctor for a proper diagnosis and treatment of ADHD. Only a doctor can decide whether medication is right for you or your child.
CONCERTA® should not be taken by patients with: significant anxiety, tension, or agitation; allergies to methylphenidate or other ingredients in CONCERTA®; glaucoma; Tourette's syndrome, tics, or family history of Tourette's syndrome.
Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if your child has had problems with alcohol or drugs, has had depression, abnormal thoughts or visions, bipolar disorder, seizures, high blood pressure or has had any heart problems or defects. If your child develops abnormal thinking or hallucinations, abnormal, extreme moods and/or excessive activity, or if aggressive behavior or hostility develops or worsens while taking CONCERTA®, consult your healthcare professional.
The most common adverse events reported in children receiving up to 54 mg were headache, upper respiratory tract infection and abdominal pain. The most common adverse events reported by adolescents receiving up to 72 mg were headache, accidental injury and insomnia.
See Full U.S. Prescribing Information and Medication Guide for CONCERTA®.
